作者
Maria Carmina Castiello,Chiara Brandas,Samuele Ferrari,Simona Porcellini,Nicolò Sacchetti,Daniele Canarutto,Elena Drăghici,Ivan Merelli,Matteo Barcella,Gabriele Pelosi,Valentina Vavassori,Angelica Varesi,Aurélien Jacob,Serena Scala,Luca Basso‐Ricci,Marianna Paulis,Dario Strina,Martina Di Verniere,Lucia Sergi Sergi,Marta Serafini,Steven M. Holland,Jenna Bergerson,Suk See De Ravin,Harry L. Malech,Francesca Pala,Marita Bosticardo,Chiara Brombin,Federica Cugnata,Enrica Calzoni,Gay M. Crooks,Luigi D. Notarangelo,Pietro Genovese,Luigi Naldini,Anna Villa
摘要
Recombination activating genes ( RAGs ) are tightly regulated during lymphoid differentiation, and their mutations cause a spectrum of severe immunological disorders. Hematopoietic stem and progenitor cell (HSPC) transplantation is the treatment of choice but is limited by donor availability and toxicity. To overcome these issues, we developed gene editing strategies targeting a corrective sequence into the human RAG1 gene by homology-directed repair (HDR) and validated them by tailored two-dimensional, three-dimensional, and in vivo xenotransplant platforms to assess rescue of expression and function. Whereas integration into intron 1 of RAG1 achieved suboptimal correction, in-frame insertion into exon 2 drove physiologic human RAG1 expression and activity, allowing disruption of the dominant-negative effects of unrepaired hypomorphic alleles. Enhanced HDR-mediated gene editing enabled the correction of human RAG1 in HSPCs from patients with hypomorphic RAG1 mutations to overcome T and B cell differentiation blocks. Gene correction efficiency exceeded the minimal proportion of functional HSPCs required to rescue immunodeficiency in Rag1 –/– mice, supporting the clinical translation of HSPC gene editing for the treatment of RAG1 deficiency.